단백질 발현 시장 : 제공 제품별, 유형별, 워크플로우별, 사업 규모별, 단백질 모달리티별, 용도별, 최종사용자별, 지역별 - 예측(-2031년)

The global protein expression market is estimated to reach USD 7.65 billion by 2031, up from USD 5.14 billion in 2026, at a CAGR of 8.3% from 2026 to 2031. The global protein expression market is projected to witness strong growth over the forecast period, driven by the expanding biologics and biosimilars pipeline, increasing demand for recombinant proteins, and growth in advanced modalities such as cell and gene therapies and mRNA products.

Market estimates indicate robust expansion through 2031, supported by technological advancements in expression systems and rising biologics manufacturing activities. However, high costs of advanced expression technologies, process scalability challenges, the need for specialized expertise, and varying regulatory requirements across regions are expected to restrain broader market growth.

"The product segment accounted for the largest share, by offering, in 2025."

Based on offerings, the protein expression market is broadly segmented into products and services. In 2025, products accounted for the largest share of the protein expression market, driven by their extensive use in routine protein production workflows, including cell culture, transfection, vector preparation, protein purification, and expression optimization. Their ease of use, recurring purchase requirements, and compatibility with automated and high-throughput platforms make them essential across research and manufacturing environments. Additionally, their cost-effectiveness and ability to enable reproducible, efficient protein production continue to drive strong demand from biopharmaceutical companies, CROs, academic institutions, and research laboratories globally.

"Mammalian expression systems accounted for the largest share of the protein expression market, by type, in 2025."

Based on type, the global protein expression market is segmented into mammalian, prokaryotic, insect, yeast, cell-free, and algal & plant-based expression systems. The mammalian expression systems segment accounted for the largest share of the protein expression market in 2025, due to its widespread use in producing complex recombinant proteins, monoclonal antibodies, and therapeutic biologics. These systems enable proper protein folding, post-translational modifications, and glycosylation patterns essential for biopharmaceutical applications. Additionally, the expanding biologics pipeline, increasing demand for high-quality therapeutic proteins, and growing commercial-scale manufacturing activities continue to strengthen the segment's leading market position globally.

"The Asia Pacific is growing at the highest CAGR in the protein expression market from 2026 to 2031."

The protein expression market is segmented into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. During the forecast period, the Asia Pacific region is estimated to grow at the highest CAGR, driven by expanding biopharmaceutical manufacturing, rising investments in biotechnology research, and increasing demand for biologics and biosimilars. Growth is further driven by the rapid expansion of contract research and manufacturing organizations (CROs/CDMOs), improvements in healthcare and research infrastructure, and the increasing adoption of advanced protein expression technologies. Additionally, the presence of major regional and global players, including Samsung Biologics and WuXi AppTec, continues to strengthen biologics development and protein production capabilities across the region.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side - 70% and Demand Side - 30%
• By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 - 30%
• By Designation: CXOs and Directors - 30%, Managers - 45%, and Others - 25%
• By Region: North America - 40%, Europe - 25%, Asia Pacific - 20%, Latin America - 10%, and the Middle East - 5%

List of Companies Profiled in the Report

• Thermo Fisher Scientific Inc.
• Merck Kgaa
• Danaher Corporation
• Agilent Technologies, Inc
• Sartorius Ag
• Genscript
• Takara Bio Inc.
• Bio-Rad Laboratories, Inc
• QIAGEN
• Charles River Laboratories
• Corning Incorporated
• Lonza
• Fujifilm Corporation
• Syngene International
• Lgc Limited
• Eurofins Scientific
• Ajinomoto Co., Inc

Research Coverage

This research report categorizes the protein expression market by offering, type, workflow, scale of operation, protein modality, application, by end user (product & service end users), and by region. The scope of the report covers detailed information regarding the major factors, such as drivers, challenges, opportunities, and restraints, influencing the growth of the protein expression market. A detailed analysis of the key industry players has been done to provide insights into their business overview, product portfolio, key strategies such as product and service approvals and launches, collaborations, partnerships, expansions, agreements, and recent developments associated with the protein expression market. This report covers competitive analysis of top players and upcoming startups in the protein expression market ecosystem.

Key Benefits of Buying the Report

The report will help market leaders/new entrants by providing the closest approximations of revenue for the overall protein expression market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their business more effectively and develop suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide information on key market drivers, restraints, opportunities, and challenges.

The report provides insights into the following pointers:

• Analysis of key drivers (increasing global biologics and biosimilar pipeline, rising government and venture capital R&D funding, continuous innovation in expression technologies), restraints (high capital and operational costs), opportunities (emerging algal expression systems and broader adoption of platforms such as cell-free, plant-based expression systems, AI/ML-driven expression optimization) and challenges (scalability Challenge from bench to GMP manufacturing) influencing the growth of protein expression market
• Product Development/Innovation: Detailed insights on newly launched products of the protein expression market
• Market Development: Comprehensive information about lucrative markets - the report analyses the protein expression market across varied regions
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the protein expression market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players such as Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Danaher Corporation (US), Agilent Technologies, Inc. (US), Sartorius AG (Germany), among others

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 MARKET SCOPE
  • 1.3.1 MARKETS COVERED
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS

2 EXECUTIVE SUMMARY

• 2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS
• 2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS
• 2.3 DISRUPTIVE TRENDS SHAPING THE MARKET
• 2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS
• 2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST

3 PREMIUM INSIGHTS

• 3.1 PROTEIN EXPRESSION MARKET OVERVIEW
• 3.2 PROTEIN EXPRESSION MARKET, BY OFFERING & REGION
• 3.3 PROTEIN EXPRESSION MARKET: GEOGRAPHIC SNAPSHOT

4 MARKET OVERVIEW

• 4.1 INTRODUCTION
• 4.2 MARKET DYNAMICS
  • 4.2.1 DRIVERS
    • 4.2.1.1 Increasing global biologics and biosimilars pipeline
    • 4.2.1.2 Rising government and venture capital R&D funding
    • 4.2.1.3 Continuous innovation in expression technologies
  • 4.2.2 RESTRAINTS
    • 4.2.2.1 High capital and operational costs
  • 4.2.3 OPPORTUNITY
    • 4.2.3.1 Emerging algal expression systems and rising adoption of advanced platforms
    • 4.2.3.2 Al/ML-driven expression optimization
  • 4.2.4 CHALLENGES
    • 4.2.4.1 Scalability challenges from bench to GMP manufacturing
• 4.3 UNMET NEEDS AND WHITE SPACES
• 4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
• 4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS

5 INDUSTRY TRENDS

• 5.1 PORTER'S FIVE FORCES ANALYSIS
  • 5.1.1 THREAT OF NEW ENTRANTS
  • 5.1.2 THREAT OF SUBSTITUTES
  • 5.1.3 BARGAINING POWER OF BUYERS
  • 5.1.4 BARGAINING POWER OF SUPPLIERS
  • 5.1.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.2 MACROECONOMIC OUTLOOK
  • 5.2.1 INTRODUCTION
  • 5.2.2 GDP TRENDS AND FORECAST
  • 5.2.3 TRENDS IN GLOBAL PROTEIN EXPRESSION MARKET
• 5.3 VALUE CHAIN ANALYSIS
  • 5.3.1 PROTEIN EXPRESSION PRODUCTS
  • 5.3.2 PROTEIN EXPRESSION SERVICES
• 5.4 ECOSYSTEM ANALYSIS
• 5.5 PRICING ANALYSIS
  • 5.5.1 AVERAGE SELLING PRICE TREND, BY KEY PLAYER, 2023-2025
  • 5.5.2 INDICATIVE SELLING PRICE, BY REGION, 2025
• 5.6 TRADE ANALYSIS
  • 5.6.1 IMPORT SCENARIO FOR HS CODE 902781
  • 5.6.2 EXPORT SCENARIO FOR HS CODE 902781
• 5.7 KEY CONFERENCES & EVENTS
• 5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.9 INVESTMENT/FUNDING SCENARIO
• 5.10 IMPACT OF US TARIFFS-PROTEIN EXPRESSION MARKET
  • 5.10.1 INTRODUCTION
  • 5.10.2 KEY TARIFF RATES
  • 5.10.3 PRICE IMPACT ANALYSIS
  • 5.10.4 IMPACT ON COUNTRIES/REGIONS
    • 5.10.4.1 North America
    • 5.10.4.2 Europe
    • 5.10.4.3 Asia Pacific
  • 5.10.5 IMPACT ON END-USE INDUSTRIES
    • 5.10.5.1 Pharmaceutical and biotechnology companies
    • 5.10.5.2 Academic & Research Institutes
    • 5.10.5.3 CROs & CDMOs
• 5.11 BIOMANUFACTURING CAPACITY
• 5.12 NIH FUNDING FOR PROTEIN-RELATED RESEARCH

6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS

• 6.1 KEY TECHNOLOGIES
  • 6.1.1 RECOMBINANT DNA TECHNOLOGY
  • 6.1.2 TRANSFECTION TECHNOLOGIES
• 6.2 ADJACENT TECHNOLOGIES
  • 6.2.1 EXTRACTION TECHNOLOGIES
• 6.3 COMPLEMENTARY TECHNOLOGIES
  • 6.3.1 HIGH-THROUGHPUT TECHNOLOGIES
  • 6.3.2 COMPUTATION PROTEIN DESIGNING
• 6.4 TECHNOLOGY/PRODUCT ROADMAP
• 6.5 PATENT ANALYSIS
  • 6.5.1 TOP APPLICANTS/OWNERS (COMPANIES) FOR PROTEIN EXPRESSION PATENTS, 2015-2025
• 6.6 FUTURE APPLICATIONS
• 6.7 IMPACT OF AI/GEN AI ON PROTEIN EXPRESSION MARKET
  • 6.7.1 TOP USE CASES AND MARKET POTENTIAL
  • 6.7.2 CASE STUDIES OF AI IMPLEMENTATION IN PROTEIN EXPRESSION MARKET
  • 6.7.3 INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS
  • 6.7.4 CLIENTS' READINESS TO ADOPT GENERATIVE AI IN PROTEIN EXPRESSION MARKET

7 SUSTAINABILITY AND REGULATORY LANDSCAPE

• 7.1 REGIONAL REGULATIONS AND COMPLIANCE
  • 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 7.1.2 REGULATORY FRAMEWORK
  • 7.1.3 INDUSTRY STANDARDS
• 7.2 SUSTAINABILITY IMPACT AND REGULATORY POLICY INITIATIVES
• 7.3 CERTIFICATIONS, LABELING, AND ECO-STANDARDS

8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR

• 8.1 DECISION-MAKING PROCESS
• 8.2 KEY STAKEHOLDERS AND BUYING EVALUATION CRITERIA
  • 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 8.2.2 KEY BUYING CRITERIA, BY END USER
• 8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
• 8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
• 8.5 MARKET PROFITABILITY

9 PROTEIN EXPRESSION MARKET, BY OFFERING

• 9.1 INTRODUCTION
• 9.2 PRODUCTS
  • 9.2.1 REAGENTS
    • 9.2.1.1 Culture media & supplements
      • 9.2.1.1.1 Optimized and GMP-ready media formulations to support scalable protein expression
    • 9.2.1.2 Expression vectors & plasmids
      • 9.2.1.2.1 Growing production of complex proteins to propel market
    • 9.2.1.3 Transduction & transfection reagents
      • 9.2.1.3.1 High-efficiency gene delivery reagents to improve transient and stable protein expression
    • 9.2.1.4 Competent cells
      • 9.2.1.4.1 Increasing demand for therapeutic proteins to expedite growth
    • 9.2.1.5 Other reagents
  • 9.2.2 INSTRUMENTS
    • 9.2.2.1 Bioreactors & fermenters
      • 9.2.2.1.1 Rising biologics research to drive adoption of advanced bioreactor systems
    • 9.2.2.2 Chromatography systems
      • 9.2.2.2.1 Expanding recombinant protein and antibody research accelerates demand for automated lab-scale systems
    • 9.2.2.3 Analytical instruments
      • 9.2.2.3.1 Rising need for rapid protein quality assessment and characterization drives demand for analytical instruments
    • 9.2.2.4 Liquid handling & automated systems
      • 9.2.2.4.1 High-throughput expression screening and workflow miniaturization to propel adoption
    • 9.2.2.5 Filtration systems
      • 9.2.2.5.1 Growing need for rapid and scalable post-expression processing driving global adoption
    • 9.2.2.6 Other instruments
  • 9.2.3 CONSUMABLES
    • 9.2.3.1 Chromatography & purification consumables
      • 9.2.3.1.1 Increasing need for high-purity recombinant proteins is accelerating adoption
    • 9.2.3.2 Filtration & separation consumables
      • 9.2.3.2.1 Rising demand for rapid, small-scale protein processing workflows is driving growth
    • 9.2.3.3 Other consumables
  • 9.2.4 KITS
    • 9.2.4.1 Expression kits
      • 9.2.4.1.1 Standardized, high-throughput expression kits accelerate recombinant protein discovery and workflow reproducibility
    • 9.2.4.2 Cloning & mutagenesis kits
      • 9.2.4.2.1 Rapid construct engineering kits to accelerate expression-ready clone development
    • 9.2.4.3 Other kits
  • 9.2.5 SOFTWARE
    • 9.2.5.1 AI-enabled design, codon optimization, and workflow informatics drive software adoption
• 9.3 SERVICES
  • 9.3.1 CUSTOM PROTEIN EXPRESSION SERVICES
    • 9.3.1.1 Rising demand for specialized recombinant protein production supports expansion of custom services
  • 9.3.2 GENE SYNTHESIS & CLONING SERVICES
    • 9.3.2.1 Reduced workload, improved accuracy, optimized workflows to drive demand
  • 9.3.3 CELL LINE DEVELOPMENT (CLD) SERVICES
    • 9.3.3.1 Outsourcing of high-yield mammalian cell line development drives growth
  • 9.3.4 PROCESS DEVELOPMENT & SCALE-UP SERVICES
    • 9.3.4.1 Rising need to translate expression hits into scalable preclinical protein production supports demand growth

10 PROTEIN EXPRESSION MARKET, BY TYPE

• 10.1 INTRODUCTION
• 10.2 MAMMALIAN CELL EXPRESSION SYSTEMS
  • 10.2.1 CHINESE HAMSTER OVARY (CHO) CELL SYSTEMS
    • 10.2.1.1 High viability, rapid growth, and improved expression levels to support growth
  • 10.2.2 HUMAN EMBRYONIC KIDNEY (HEK 293) CELL SYSTEMS
    • 10.2.2.1 Wide usage in transient transfection studies to augment growth
  • 10.2.3 OTHER MAMMALIAN CELL EXPRESSION SYSTEMS
• 10.3 PROKARYOTIC EXPRESSION SYSTEMS
  • 10.3.1 ESCHERICHIA COLI SYSTEMS
    • 10.3.1.1 Increasing use of E. coli systems for commercial protein production to support market
  • 10.3.2 BACILLUS SYSTEMS
    • 10.3.2.1 Efficient secretion capabilities drive growing adoption
  • 10.3.3 OTHER PROKARYOTIC EXPRESSION SYSTEMS
• 10.4 INSECT CELL EXPRESSION SYSTEMS
  • 10.4.1 BACULOVIRUS SYSTEMS
    • 10.4.1.1 High protein yield and expression levels of intracellular proteins through the baculovirus expression system to support growth
  • 10.4.2 OTHER INSECT CELL SYSTEMS
• 10.5 YEAST EXPRESSION SYSTEMS
  • 10.5.1 PICHIA SYSTEMS
    • 10.5.1.1 High scalability and efficient protein production to support growth
  • 10.5.2 SACCHAROMYCES SYSTEMS
    • 10.5.2.1 Efficient secretory pathways and scalable recombinant protein production to support market growth
  • 10.5.3 OTHER YEAST EXPRESSION SYSTEMS
• 10.6 CELL-FREE EXPRESSION SYSTEMS
  • 10.6.1 E. COLI LYSATE-BASED SYSTEMS
    • 10.6.1.1 Rapid and flexible platforms for protein synthesis to drive adoption
  • 10.6.2 OTHER CELL-FREE EXPRESSION SYSTEMS
• 10.7 ALGAL & PLANT-BASED EXPRESSION SYSTEMS
  • 10.7.1 GROWTH IN VACCINES MARKET TO SUPPORT SEGMENT

11 PROTEIN EXPRESSION MARKET, BY WORKFLOW

• 11.1 INTRODUCTION
• 11.2 CLONING & TRANSFECTION
  • 11.2.1 CONTINUOUS REPLENISHMENT OF CONSUMABLES AND REAGENTS TO SUPPORT THE MARKET
• 11.3 TRANSCRIPTION, TRANSLATION, AND POST-TRANSLATIONAL MODIFICATION (PTM)
  • 11.3.1 GROWING NEED FOR FUNCTIONAL AND STABLE PROTEINS TO DRIVE MARKET
• 11.4 EXTRACTION, PURIFICATION, AND CHARACTERIZATION
  • 11.4.1 NEED TO ADHERE TO REQUIRED STANDARDS FOR SUITABLE APPLICATIONS TO DRIVE MARKET

12 PROTEIN EXPRESSION PRODUCTS MARKET, BY SCALE OF OPERATION

• 12.1 INTRODUCTION
• 12.2 DISCOVERY & RESEARCH SCALE
  • 12.2.1 EXPANDING BIOLOGICS PIPELINE AND FOCUS ON COMPUTATIONALLY DESIGNED PROTEINS TO AID GROWTH
• 12.3 PRECLINICAL & CHARACTERIZATION SCALE
  • 12.3.1 SIGNIFICANT NUMBER OF BIOLOGIC CANDIDATES ENTERING PRE-CLINICAL DEVELOPMENT TO BOOST THE MARKET
• 12.4 PROCESS DEVELOPMENT & PILOT SCALE
  • 12.4.1 INCREASING OUTSOURCING OF EXPRESSION AT PROCESS DEVELOPMENT SCALE TO SUPPORT GROWTH

13 PROTEIN EXPRESSION PRODUCTS MARKET, BY PROTEIN MODALITY

• 13.1 INTRODUCTION
• 13.2 MONOCLONAL ANTIBODIES & DERIVATIVES
  • 13.2.1 EXPANDING ANTIBODY DISCOVERY, BISPECIFIC DEVELOPMENT, AND MAMMALIAN EXPRESSION OPTIMIZATION DRIVE DEMAND
• 13.3 RECOMBINANT THERAPEUTIC PROTEINS
  • 13.3.1 INCREASING DEVELOPMENT OF RECOMBINANT BIOLOGICS AND ENGINEERED THERAPEUTIC PROTEINS IS DRIVING DEMAND
• 13.4 VACCINES
  • 13.4.1 RISING DEMAND FOR RECOMBINANT ANTIGENS AND NEXT-GENERATION VACCINE PLATFORMS DRIVES PROTEIN EXPRESSION ADOPTION IN VACCINE RESEARCH
• 13.5 ENZYMES & CATALYTIC PROTEINS
  • 13.5.1 EXPANDING ENZYME ENGINEERING AND BIOCATALYSIS APPLICATIONS ARE ACCELERATING DEMAND
• 13.6 OTHER PROTEINS

14 PROTEIN EXPRESSION MARKET, BY APPLICATION

• 14.1 INTRODUCTION
• 14.2 THERAPEUTIC APPLICATIONS
  • 14.2.1 RISING DEMAND FOR BIOLOGICS THERAPIES TO FACILITATE GROWTH
• 14.3 RESEARCH APPLICATIONS
  • 14.3.1 GROWING INTEREST IN PROTEOMICS, GENOMICS, AND DRUG DISCOVERY TO BOOST MARKET
• 14.4 INDUSTRIAL APPLICATIONS
  • 14.4.1 INCREASING USE OF PROTEINS IN COSMETICS, TEXTILES, AND INDUSTRIAL ENZYMES TO PROMOTE GROWTH
• 14.5 DIAGNOSTIC APPLICATIONS
  • 14.5.1 RECOMBINANT PROTEINS AND ASSAY-READY REAGENTS TO STRENGTHEN DIAGNOSTIC DEVELOPMENT

15 PROTEIN EXPRESSION PRODUCTS MARKET, BY END USER

• 15.1 INTRODUCTION
• 15.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • 15.2.1 RISING INVESTMENT IN BIOLOGICS AND INCREASING APPROVALS FOR BIOLOGICS TO SUPPORT GROWTH
• 15.3 CROS & CDMOS
  • 15.3.1 INCREASE IN OUTSOURCING AND COLLABORATIONS FOR PHARMACEUTICAL MANUFACTURING TO BOOST MARKET
• 15.4 ACADEMIC & RESEARCH INSTITUTES
  • 15.4.1 INCREASING GOVERNMENT AND PRIVATE FUNDING TO SUPPORT MARKET
• 15.5 OTHER END USERS

16 PROTEIN EXPRESSION SERVICES MARKET, BY END USER

• 16.1 INTRODUCTION
• 16.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • 16.2.1 INCREASING SHIFT TOWARD DRUG DEVELOPMENT OUTSOURCING TO FAVOR GROWTH
• 16.3 ACADEMIC & RESEARCH INSTITUTES
  • 16.3.1 RISING PARTNERSHIPS BETWEEN ACADEMIA AND CONTRACT RESEARCH ORGANIZATIONS TO AID GROWTH
• 16.4 OTHER END USERS

17 PROTEIN EXPRESSION MARKET, BY REGION

• 17.1 INTRODUCTION
• 17.2 NORTH AMERICA
  • 17.2.1 US
    • 17.2.1.1 Growing focus on developing new therapeutics and protein-based drugs to drive market
  • 17.2.2 CANADA
    • 17.2.2.1 Increasing incidence of cancer and prevalence of public-private partnerships to sustain growth
• 17.3 EUROPE
  • 17.3.1 GERMANY
    • 17.3.1.1 Increasing proteomics-based research and healthcare investments to promote growth
  • 17.3.2 UK
    • 17.3.2.1 Growing development of immunotherapies, vaccines, and proteomics to fuel market
  • 17.3.3 FRANCE
    • 17.3.3.1 Rise in funding for proteomics and genomics to spur growth
  • 17.3.4 ITALY
    • 17.3.4.1 Growing life science research supported by universities and research institutions to boost market
  • 17.3.5 SPAIN
    • 17.3.5.1 Growing expansion of biotech companies and increasing R&D expenditure to drive market
  • 17.3.6 NETHERLANDS
    • 17.3.6.1 Presence of advanced infrastructure to fuel market
  • 17.3.7 REST OF EUROPE
• 17.4 ASIA PACIFIC
  • 17.4.1 CHINA
    • 17.4.1.1 Rising biologics development driving market growth
  • 17.4.2 JAPAN
    • 17.4.2.1 Growing government initiatives and expansion of biopharma companies to boost market
  • 17.4.3 INDIA
    • 17.4.3.1 Rising collaborations between private sector and academia to facilitate growth
  • 17.4.4 AUSTRALIA
    • 17.4.4.1 Strong regulatory framework, clinical innovation, and global partnerships drive market growth
  • 17.4.5 SOUTH KOREA
    • 17.4.5.1 Increasing research & development of novel therapies to facilitate growth
  • 17.4.6 REST OF ASIA PACIFIC
• 17.5 LATIN AMERICA
  • 17.5.1 BRAZIL
    • 17.5.1.1 Growing industrial investments to propel market
  • 17.5.2 MEXICO
    • 17.5.2.1 Increasing government support for biopharmaceutical production to drive market
  • 17.5.3 ARGENTINA
    • 17.5.3.1 Rise in biotechnology and pharmaceutical research & development to augment growth
  • 17.5.4 REST OF LATIN AMERICA
• 17.6 MIDDLE EAST
  • 17.6.1 GCC COUNTRIES
    • 17.6.1.1 Saudi Arabia
      • 17.6.1.1.1 Rising demand for biologics and increasing healthcare investments to support market growth
    • 17.6.1.2 United Arab Emirates
      • 17.6.1.2.1 Developing biopharma sector to drive market
    • 17.6.1.3 Rest of GCC countries
  • 17.6.2 REST OF MIDDLE EAST
• 17.7 AFRICA

18 COMPETITIVE LANDSCAPE

• 18.1 OVERVIEW
• 18.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 18.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN PROTEIN EXPRESSION MARKET
• 18.3 REVENUE ANALYSIS
• 18.4 MARKET SHARE ANALYSIS
• 18.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
  • 18.5.1 STARS
  • 18.5.2 EMERGING LEADERS
  • 18.5.3 PERVASIVE PLAYERS
  • 18.5.4 PARTICIPANTS
  • 18.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
    • 18.5.5.1 Company footprint
    • 18.5.5.2 Region footprint
    • 18.5.5.3 Offering footprint
    • 18.5.5.4 Type footprint
    • 18.5.5.5 Application footprint
• 18.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
  • 18.6.1 PROGRESSIVE COMPANIES
  • 18.6.2 RESPONSIVE COMPANIES
  • 18.6.3 DYNAMIC COMPANIES
  • 18.6.4 STARTING BLOCKS
  • 18.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
    • 18.6.5.1 Detailed list of key startups/SMEs
    • 18.6.5.2 Competitive benchmarking of key startups/SMEs
• 18.7 COMPANY VALUATION AND FINANCIAL METRICS
  • 18.7.1 COMPANY VALUATION
  • 18.7.2 FINANCIAL METRICS
• 18.8 BRAND/PRODUCT COMPARISON
• 18.9 COMPETITIVE SCENARIO
  • 18.9.1 PRODUCT & SERVICE LAUNCHES
  • 18.9.2 DEALS
  • 18.9.3 EXPANSIONS

19 COMPANY PROFILES

• 19.1 MAJOR PLAYERS
  • 19.1.1 THERMO FISHER SCIENTIFIC INC.
    • 19.1.1.1 Business overview
    • 19.1.1.2 Products & services offered
    • 19.1.1.3 Recent developments
      • 19.1.1.3.1 Product & service launches
      • 19.1.1.3.2 Deals
      • 19.1.1.3.3 Expansions
    • 19.1.1.4 MnM view
      • 19.1.1.4.1 Key strengths
      • 19.1.1.4.2 Strategic choices
      • 19.1.1.4.3 Weaknesses and competitive threats
  • 19.1.2 MERCK KGAA
    • 19.1.2.1 Business overview
    • 19.1.2.2 Products & services offered
    • 19.1.2.3 Recent developments
      • 19.1.2.3.1 Deals
      • 19.1.2.3.2 Expansions
    • 19.1.2.4 MnM view
      • 19.1.2.4.1 Key strengths
      • 19.1.2.4.2 Strategic choices
      • 19.1.2.4.3 Weaknesses and competitive threats
  • 19.1.3 DANAHER CORPORATION
    • 19.1.3.1 Business overview
    • 19.1.3.2 Products & services offered
    • 19.1.3.3 Recent developments
      • 19.1.3.3.1 Product launches
      • 19.1.3.3.2 Deals
      • 19.1.3.3.3 Expansions
    • 19.1.3.4 MnM view
      • 19.1.3.4.1 Key strengths
      • 19.1.3.4.2 Strategic choices
      • 19.1.3.4.3 Weaknesses and competitive threats
  • 19.1.4 AGILENT TECHNOLOGIES, INC.
    • 19.1.4.1 Business overview
    • 19.1.4.2 Products & services offered
    • 19.1.4.3 Recent developments
      • 19.1.4.3.1 Product launches
      • 19.1.4.3.2 Deals
    • 19.1.4.4 MnM view
      • 19.1.4.4.1 Key strengths
      • 19.1.4.4.2 Strategic choices
      • 19.1.4.4.3 Weaknesses and competitive threats
  • 19.1.5 SARTORIUS AG
    • 19.1.5.1 Business overview
    • 19.1.5.2 Products & services offered
    • 19.1.5.3 Recent developments
      • 19.1.5.3.1 Deals
      • 19.1.5.3.2 Expansions
    • 19.1.5.4 MnM view
      • 19.1.5.4.1 Key strength
      • 19.1.5.4.2 Strategic choices
      • 19.1.5.4.3 Weaknesses and competitive threats
  • 19.1.6 GENSCRIPT
    • 19.1.6.1 Business overview
    • 19.1.6.2 Products & services offered
    • 19.1.6.3 Recent developments
      • 19.1.6.3.1 Product/Service launches
  • 19.1.7 TAKARA BIO INC.
    • 19.1.7.1 Business overview
    • 19.1.7.2 Products & services offered
    • 19.1.7.3 Recent developments
      • 19.1.7.3.1 Expansions
  • 19.1.8 BIO-RAD LABORATORIES, INC.
    • 19.1.8.1 Business overview
    • 19.1.8.2 Products & services offered
    • 19.1.8.3 Recent developments
      • 19.1.8.3.1 Product launches
      • 19.1.8.3.2 Deals
  • 19.1.9 QIAGEN
    • 19.1.9.1 Business overview
    • 19.1.9.2 Products & services offered
    • 19.1.9.3 Recent developments
      • 19.1.9.3.1 Product launches
      • 19.1.9.3.2 Deals
  • 19.1.10 CHARLES RIVER LABORATORIES
    • 19.1.10.1 Business overview
    • 19.1.10.2 Products & services offered
    • 19.1.10.3 Recent developments
      • 19.1.10.3.1 Product/Service launches
  • 19.1.11 CORNING INCORPORATED
    • 19.1.11.1 Business overview
    • 19.1.11.2 Products & services offered
    • 19.1.11.3 Recent developments
      • 19.1.11.3.1 Product launches
  • 19.1.12 LONZA
    • 19.1.12.1 Business overview
    • 19.1.12.2 Products & services offered
    • 19.1.12.3 Recent developments
      • 19.1.12.3.1 Product launches
      • 19.1.12.3.2 Deals
  • 19.1.13 FUJIFILM HOLDINGS CORPORATION
    • 19.1.13.1 Business overview
    • 19.1.13.2 Products & services offered
    • 19.1.13.3 Recent developments
      • 19.1.13.3.1 Product launches
      • 19.1.13.3.2 Expansions
  • 19.1.14 SYNGENE INTERNATIONAL LIMITED
    • 19.1.14.1 Business overview
    • 19.1.14.2 Products & services offered
    • 19.1.14.3 Recent developments
      • 19.1.14.3.1 Product launches
  • 19.1.15 LGC LIMITED
    • 19.1.15.1 Business overview
    • 19.1.15.2 Products & services offered
  • 19.1.16 EUROFINS SCIENTIFIC
    • 19.1.16.1 Business overview
    • 19.1.16.2 Products & services offered
    • 19.1.16.3 Recent developments
      • 19.1.16.3.1 Expansions
  • 19.1.17 AJINOMOTO CO., INC.
    • 19.1.17.1 Business overview
    • 19.1.17.2 Products & services offered
    • 19.1.17.3 Recent developments
      • 19.1.17.3.1 Deals
• 19.2 OTHER PLAYERS
  • 19.2.1 PROMEGA CORPORATION
  • 19.2.2 SINO BIOLOGICAL, INC.
  • 19.2.3 RAYBIOTECH, INC.
  • 19.2.4 BIONEER CORPORATION
  • 19.2.5 ORIGENE TECHNOLOGIES, INC.
  • 19.2.6 NEW ENGLAND BIOLABS
  • 19.2.7 ACCURUS BIOSCIENCES
  • 19.2.8 ARAGEN LIFE SCIENCES LTD.
  • 19.2.9 OXFORD EXPRESSION TECHNOLOGIES LTD
  • 19.2.10 PROTEOGENIX INC.
  • 19.2.11 ABEOMICS

20 RESEARCH METHODOLOGY

• 20.1 RESEARCH DATA
  • 20.1.1 SECONDARY DATA
  • 20.1.2 PRIMARY DATA
• 20.2 MARKET ESTIMATION METHODOLOGY
  • 20.2.1 MARKET SIZE ESTIMATION
  • 20.2.2 INSIGHTS OF PRIMARY EXPERTS
  • 20.2.3 TOP-DOWN APPROACH
• 20.3 MARKET GROWTH RATE PROJECTIONS
• 20.4 MARKET BREAKDOWN AND DATA TRIANGULATION
• 20.5 RESEARCH ASSUMPTIONS
• 20.6 RESEARCH LIMITATIONS
• 20.7 RISK ANALYSIS

21 APPENDIX

• 21.1 DISCUSSION GUIDE
• 21.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 21.3 CUSTOMIZATION OPTIONS
• 21.4 RELATED REPORTS
• 21.5 AUTHOR DETAILS